Continuous infusion of beta-lactam antibiotics

Connecticut Medicine

Volumn 63, Issue 5, 1999, Pages 275-277

  Grant, Edward ^b   Nicolau, David P ^b   Nightingale, Charles H ^b   Quintiliani, Richard ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; GENTAMICIN; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC THERAPY; BACTERIAL PNEUMONIA; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; CONTINUOUS INFUSION; COST CONTROL; HEALTH CARE COST; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; REVIEW;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CONNECTICUT; COST SAVINGS; HUMANS; INFUSIONS, INTRAVENOUS;

EID: 0032988169     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Gilbert DN: Once daily aminoglycoside therapy. Antimicob Agents Chemother 1991; 35:399-405.
2. Craig WA: Interrelationships between pharmacokinetic and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22:8-96.
3. Vogelman B, Gundmundson S, Leggett J. et al: Correlation of antimicrobial pharmacokinetic parameters with efficacy in an animal model. Infect Dis 1988; 158:831-47.
4. Onyeji CO, Nicolau DP, Nightingale CH, Quintiliani R: Optimal times above MICs of ceftibuten and ceficlor in experimental intra abdominal infections. Antimicrob Agent Chemother 1994; 38:1112-7.
5. Nightingale CH, Quintiliani R, Nicolau DP: Intelligent dosing of antimicrobials. In: Remington JS, Swartz MN (eds.): Current Clinical topics in Infectious Diseases. Cambridge, Mass.: Blackwell Scientific; 1994:252-65.
6. Nicolau DP, Nightingale CH, Quintiliani R: Continuous infusion - lactams: A pharmacodynamic approach. IDCP 1996; 5:432-4.
7. Nicolau DP, Nightingale CH, Quintiliani R: Antibiotic kinetics and dynamics for the clinician. Antimicrobial Therapy 1995; 79:477-95.
8. Peterson LR, Gerding DN, Fasching CE: Effects of method of antibiotic administration on extravascular penetration: Cross-over study of cefazolin given by intermittent injection or constant infusion. J Antimicob Chemother 1981; 7:71-9.
9. Plorde J, Garcia M, Petersdorf RG: Studies on the pathogenesis of meningitis. IV penicillin levels in the cerebrospinal fluid in experimental meningitis. J Lan Clin Med 1964; 64:960-9.
10. Ambrose PG, Quintiliani R, Nightingale CH, Nicolau DP: Continuous vs intermittent infusion of cefuroxime for the treatment of community-acquired pneumonia. IDCP 1998; 7:463-70.
11. Nicolau DP, Lacy MK, McNabb J, et al: Pharmacokinetics of continuous and intermittent ceftazidime in intensive care unit patients with nosocomial pneumonia. IDCP 1999; 8:45-9.
12. Ambrose PG, Bui K, Richerson M, et al: Pharmacokinetic and economic evaluation of piperacillin/tazobactam administered either as a continuous or intermittent infusion with once-daily gentamicin. IDCP 1999:9 In-Press.
13. Zosyn Package Insert. Lederle Piperacillin, Inc. 1997.
14. Performance Standards for Antimicrobial Susceptibility Testing; Eighth Informational Supplement. Approved Standard NCCLS Document M100-S8, vol 18, no. 1, NCCLS, Wayne, Penn.; January 1998.
15. Hitt CM, Patel KB, Nicolau DP, et al: Influence of Piperacillin-Tazobactam on pharmacokinetics of gentimicin given once daily. Am J Health-Syst Pharm 1997; 54:2704-8.
16. Hitt CM, Nightingale CH, Quintiliani R, Nicolau DP: Cost comparison of single daily doses of ceftriaxone vs continuous infusion of cefotaxime. Am J Health-Syst Pharm 1997; 54:1614-8.
17. Owens CA, Ambrose PG, Quintiliani R, et al: Infusion phlebitis relative incidence associated with cefuroxime administered by intermittent infusion and continuous infusion. Clin Drug Invest 1998; 15:525-9.